Biotech and Pharmaceuticals

Lilly Sues Six Companies Over Illegal Retatrutide Sales

by

Retatrutide Black Market Lawsuits Target Six Compounding Pharmacies and Online Sellers Pharmaceutical analysts note that demand for weight-loss treatments has fueled a thriving ⁠online market for products claiming to contain weight-loss drugs. Illicit sellers frequently attempt to bypass federal oversight by labeling products as “research-use only.” Testing of seized black-market inventory reveals severe safety hazards, … Read more

Johnson & Johnson (JNJ) Q2 Earnings Report: Key Takeaways

by

Johnson & Johnson surpassed Wall Street expectations for its second-quarter financial results, reporting $25.31 billion in total sales—a 6.6% increase year-over-year. Driven by strong demand for immunology drug Tremfya and oncology treatment Darzalex, the healthcare giant raised its full-year guidance, now projecting mid-point sales of $101.1 billion and adjusted earnings of $11.68 per share. Pharmaceutical … Read more

Johnson & Johnson: Beyond the Rotation Strategy

by

Johnson & Johnson (JNJ) shares are navigating a period of volatility as investors weigh the company’s pharmaceutical growth against broader market rotations and macroeconomic pressures. According to FactSet, the healthcare giant faces a critical test during its second-quarter earnings report, with analysts closely monitoring the performance of key oncology and immunology drugs to justify the … Read more

Ivonescimab Improves Survival in HARMONI-6 Trial

by

The Future of Lung Cancer Treatment: Is a ‘Keytruda Successor’ Finally Here? For over a decade, Merck’s Keytruda has stood as the undisputed titan of oncology. With over 44 FDA indications and annual sales exceeding $30 billion, it transformed lung cancer from a terminal diagnosis into a manageable condition for many. Now, the medical community … Read more

Eli Lilly’s New Vaccine Strategy: What You Need to Know

by

Eli Lilly’s Strategic Pivot: Why Vaccines Are the Next Frontier In a bold move that signals a major shift in corporate strategy, pharmaceutical giant Eli Lilly has re-entered the vaccine and infectious disease market. By acquiring three private biotech firms—Curevo, LimmaTech Biologics and Vaccine Company—in deals totaling nearly $4 billion, the company is betting that … Read more

Novo Nordisk faces Ozempic generics in Canada

by

The Ozempic Effect: What Generic GLP-1s Mean for the Future of Weight Loss and Pharma For years, the pharmaceutical world has watched the meteoric rise of semaglutide—the active ingredient in blockbuster drugs like Ozempic and Wegovy. What started as a treatment for type 2 diabetes evolved into a global cultural phenomenon, redefining how we approach … Read more

Eli Lilly to buy Ajax Therapeutics

by

Beyond the Blockbusters: The Strategic Shift in Oncology Pipelines The pharmaceutical landscape is witnessing a pivotal shift. Even as weight-loss medications have captured global headlines, industry giants are quietly reinforcing their foundations in oncology. A prime example is Eli Lilly and Company’s recent move to acquire Ajax Therapeutics for up to $2.3 billion in cash. … Read more

Trump nominates Erica Schwartz as CDC director

by

President Donald Trump has nominated Erica Schwartz to serve as the director of the Centers for Disease Control and Prevention (CDC), ending a months-long search for a permanent leader of the agency. Schwartz, who must be confirmed by the Senate, will enter the role as Health and Human Services Secretary Robert F. Kennedy Jr. Manages … Read more

Eli Lilly reaches deal to bring AI-developed drugs to global market

by

AI Revolutionizes Drug Discovery: Lilly’s $2.75 Billion Bet on Insilico The pharmaceutical industry is undergoing a seismic shift, driven by the rapid advancements in artificial intelligence. This week, Eli Lilly took a massive leap forward, announcing a $2.75 billion deal with Hong Kong-based Insilico Medicine to accelerate the development of AI-discovered drugs. This collaboration isn’t … Read more

How CNBC Cures is bringing rare disease stories to a national audience

by

CNBC Cures: A Turning Tide for Rare Disease Awareness and Innovation The launch of CNBC Cures, spearheaded by Becky Quick and her sister, marks a significant shift in how rare diseases are discussed and addressed. What began as a personal mission – driven by Quick’s own family’s experience with a rare disease diagnosis – has … Read more

© 2026 Newsy Today. All rights reserved.


For contact, advertising, copyright, issues email: [email protected]

For contact, advertising, copyright, issues email: [email protected]